How to Submit Data to swissdamed and How It Differs from EUDAMED

For years, the European medical device market operated under the assumption of seamless cross-border trade, supported by the Mutual Recognition Agreement (MRA) between Switzerland and the European Union. However, when the MRA lapsed in May 2021, the regulatory landscape fundamentally fractured. Switzerland could no longer rely on automatic recognition of EU medical device approvals, nor could the Swiss competent authority, Swissmedic, maintain its privileged access to the European Database on Medical Devices (EUDAMED).

In response, Switzerland enacted the Medical Devices Ordinance (MedDO) and the In Vitro Diagnostic Medical Devices Ordinance (IvDO), establishing its own sovereign regulatory framework. A cornerstone of this new framework is swissdamed — the Swiss Database on Medical Devices.

With the rollout of the first four EUDAMED modules nearing its mandatory enforcement date (28 May 2026), manufacturers are now facing a dual-compliance scenario. The swissdamed Actor module has been mandatory since August 2024, and the UDI Devices module opened for voluntary use in August 2025. Now, the final critical deadline is rapidly approaching: starting July 1, 2026, device registration in swissdamed will become mandatory for products placed on the Swiss market.

This article will cover what swissdamed is, how its operational architecture differs from EUDAMED, and the precise, step-by-step methodologies manufacturers must utilize to submit their critical device data accurately and compliantly before the transition periods expire.

What Is swissdamed? 

At its core, swissdamed is a highly structured, centralized regulatory database designed and operated by Swissmedic. Its primary function is to establish complete transparency, ensure post-market traceability, and facilitate rigorous market surveillance for all medical devices and in vitro diagnostics (IVDs) marketed within Switzerland and Liechtenstein.

To achieve this, swissdamed currently operates through two foundational modules: the Actors module and the UDI Devices module.

Under Article 55 para. 1 of the MedDO / Article 48 para. 1 of the IvDO, the following economic operators must register in swissdamed:

• Manufacturers domiciled in Switzerland or Liechtenstein
• Authorized representatives (CH-REPs) domiciled in Switzerland or Liechtenstein, representing foreign manufacturers
• Importers domiciled in Switzerland or Liechtenstein.

Just like in the EU, distributors are considered economic operators but are excluded from the direct database registration requirement and are not considered “Actors” under the MedDO/IvDO framework. Upon successful registration and validation by Swissmedic, the actor is issued a Swiss Single Registration Number (CHRN), which acts as their unique identifier for all subsequent regulatory activities.

From a broader regulatory perspective, swissdamed is Switzerland’s direct technical equivalent to EUDAMED. It is deeply rooted in the globally harmonized principles established by the International Medical Device Regulators Forum (IMDRF) and relies heavily on the Unique Device Identification (UDI) system. This ensures that while Switzerland operates independently of the EU MDR and IVDR, the actual data models and post-market surveillance expectations remain conceptually synchronized with European standards, preventing a total regulatory disconnect.

The Regulatory Divergence: How swissdamed Differs from EUDAMED 

While swissdamed was purposefully engineered to mirror the data structures of EUDAMED, it is critical for regulatory professionals to understand that the two systems are strictly independent. Swissmedic explicitly notes that because there is no interface between swissdamed and EUDAMED, Swissmedic cannot automatically import, sync, or pull data from the European database.

This lack of interoperability introduces several major operational impacts and structural differences that medical device manufacturers must strategically navigate:

• Jurisdictional Isolation and Dual Maintenance: The most significant impact for device manufacturers is the unavoidable burden of dual data maintenance. Entering a product’s UDI-DI and technical characteristics into EUDAMED does not grant that product legal market access in Switzerland. Manufacturers must actively establish an independent, parallel data submission pipeline specifically dedicated to swissdamed, treating it as a wholly separate regulatory obligation.
• Actor Registration Restrictions for Foreign Entities: In EUDAMED, a manufacturer based outside the EU (e.g., in the United States or Japan) can register directly in the database to obtain their Single Registration Number (SRN), provided their EU Authorized Representative verifies the request. In stark contrast, non-Swiss manufacturers cannot independently access or register themselves in the swissdamed Actors module. Instead, their legally appointed Swiss Authorized Representative (CH-REP) must initiate the registration on their behalf. Once completed, the foreign manufacturer is issued a “Mandate ID” rather than a primary CHRN.
• The CHRN vs. The SRN: The identification numbers carry different geographical weight. The Single Registration Number (SRN) issued by EUDAMED allows an economic operator to be recognized across all 27 EU Member States. The Swiss Single Registration Number (CHRN) is strictly localized; it only holds legal validity for market surveillance and vigilance reporting within the borders of Switzerland and Liechtenstein.
• Module Scope and Complexity: EUDAMED is a massive ecosystem encompassing six interconnected modules (Actors, UDI/Devices, Certificates, Clinical Investigations, Vigilance, and Market Surveillance). swissdamed is currently much narrower in scope, focusing exclusively on establishing the foundational Actors and UDI/Devices modules to regain the traceability lost when the MRA dissolved.

For manufacturers, these differences mean that regulatory affairs and master data management teams can no longer treat the European continent as a single harmonized data set. Discrepancies between the data uploaded to EUDAMED and the data uploaded to swissdamed, even for the exact same physical device, can result in market access delays or immediate customs detention at the Swiss border.

Step-by-Step Guide: How to Submit Data to swissdamed

Because swissdamed is structurally isolated from EUDAMED, the submission process requires a deliberate, methodical approach. Manufacturers cannot simply copy and paste their European compliance strategies; they must utilize specific data channels approved by Swissmedic.

Before any device data can be submitted, the prerequisite Actor registration must be finalized. For a foreign manufacturer, this means legally appointing a CH-REP, executing the mandate agreement, and having the CH-REP register the relationship in the swissdamed Actors module to generate the official Mandate ID.

Once the Actor registration is secure, manufacturers must select their methodology for populating the UDI Devices module. To maximize equivalence with the EU and minimize the IT burden on the industry, Swissmedic has designed swissdamed to accept data via three distinct pathways:

1. XML Upload (The Primary Enterprise Method): Currently, the most efficient and widely used method for submitting device data to swissdamed is through Extensible Markup Language (XML) file uploads. Recognizing that many manufacturers have already heavily invested in formatting their data for EUDAMED, Swissmedic specifically configured swissdamed to accept XML files structured in the exact EUDAMED GET DEVICE or POST DEVICE formats.
   • Why this matters: For manufacturers managing extensive product portfolios, manually retyping thousands of UDI attributes is not feasible. By utilizing a single “source of truth” database internally, regulatory teams can generate an EUDAMED-compliant XML file and simply repurpose that exact file for a bulk upload into swissdamed, drastically reducing administrative overhead and the risk of transcription errors.
2. Machine-to-Machine (M2M) Integration: Beginning in late March 2026, Swissmedic is launching direct M2M capabilities for swissdamed on its playground (testing) environment. This advanced method utilizes a REST API to facilitate direct, automated data exchanges between a manufacturer’s internal Product Lifecycle Management (PLM) or Enterprise Resource Planning (ERP) systems and the swissdamed servers. Data is typically exchanged using JSON formatting.
   • Why this matters: M2M is the gold standard for massive, multinational manufacturers. It eliminates manual file uploads entirely, automatically synchronizing device updates, status changes, and new product launches in real-time. However, establishing an M2M connection requires significant IT infrastructure, rigorous cybersecurity validation, and continuous maintenance.
3. Online Editor (Manual User Interface): Also becoming fully functional in early 2026, the online editor allows users to log directly into the swissdamed web portal and manually type in device data field by field.
   • Why this matters: While highly inefficient and prone to human error for large companies, the manual UI is a necessary lifeline for very small manufacturers or bespoke device producers who only maintain a handful of SKUs and cannot justify the cost of XML conversion software or API development.

Regardless of the chosen method, the data submitted is subjected to intense systemic validation. swissdamed employs strict cross-field dependency checks. If a submitted XML file contains an invalid Basic UDI-DI format, or if the linked CHRN does not match the registered CH-REP, the entire file will be rejected by the system. Establishing rigorous data governance and utilizing pre-validation software prior to submission is essential to avoid repetitive upload failures.

Critical Timelines and Compliance Deadlines

Regulatory professionals must integrate the following legally binding deadlines into their immediate deployment roadmaps:

• August 2024: The Actors module became strictly mandatory. Those economic operators that must be registered under the MedDO / IvDO conducting business in Switzerland must possess a valid CHRN.
• August 2025: The UDI Devices module went live for voluntary submissions, allowing proactive manufacturers to begin uploading XML files and clearing technical hurdles.
• July 1, 2026: Device registration in swissdamed becomes legally mandatory for all devices placed on the Swiss market.
• July 1, 2026 (Zero Transition): For devices that are currently subject to a reporting obligation for serious incidents, Field Safety Corrective Actions (FSCA), or adverse trends, there is absolutely no transition period. These specific devices must be fully registered in swissdamed immediately on this date to remain compliant.
• December 31, 2026: The official transition period concludes. By this date, all medical devices, IVDs, systems, and procedure packs placed on the market in Switzerland must be comprehensively and accurately registered within the swissdamed UDI Devices module.

How MedEnvoy Can Support

EUDAMED and swissdamed have been a long time coming. With their gradual rollouts nearly complete and mandatory deadlines converging in mid-to-late 2026, many manufacturers still face operational uncertainty about how to integrate these dual regulatory requirements into their existing supply chain processes without duplicating their workload.

The volume of data required, combined with the strict XML formatting rules and the mandatory reliance on a CH-REP, makes swissdamed compliance a highly technical challenge. If you have never formatted an EUDAMED-compliant XML file, or if you are struggling to manage the distinct operational responsibilities between your EU Importer and your CH-REP, MedEnvoy can help.

As an established leader in global regulatory compliance, MedEnvoy provides comprehensive, end-to-end support for both European and Swiss market access. We can act as your dedicated, legally compliant Swiss Authorized Representative (CH-REP) and Swiss Importer.

Do not wait until the 2026 bottlenecks create challenges for market access. Contact MedEnvoy today to secure your CH-REP, streamline your UDI submissions, and ensuring that your medical devices remain compliant and accessible to the patients who rely on them across Switzerland and the European Union.